Also found in: Dictionary, Thesaurus, Wikipedia.
Related to acetohexamide: acetazolamide, glyburide, tolazamide, Visken, Benserazide


any of a class of compounds that exert hypoglycemic activity by stimulating the islet tissue to secrete insulin; used to control hyperglycemia in patients with type 2 diabetes mellitus who cannot be treated solely by diet and exercise. The class includes the oral hypoglycemic agentsacetohexamide, chlorpropamide, glipizide, tolazamide, and tolbutamide.


/ac·e·to·hex·a·mide/ (as″ĕ-to-hek´sah-mīd) an oral hypoglycemic used in the treatment of type 2 diabetes mellitus.


a sulfonylurea oral antidiabetic.
indication It may be prescribed in the treatment of type 2 diabetes mellitus.
contraindications Its use is prohibited as sole therapy in type 1 diabetes mellitus, diabetic ketoacidosis, severe liver or kidney dysfunction, or known hypersensitivity to this drug or to other sulfonylureas.
adverse effects Among the most serious adverse reactions are blood dyscrasias, hypoglycemia, and allergic reactions. GI disturbances are common.


A first-generation oral sulfonylurea used to reduce glucose in type 2 diabetics whose diabetes can’t be controlled by diet.
Mechanism of action Triggers release of insulin from the pancreas.
Pharmacokinetics Metabolised in liver to an active analogue; excreted via kidneys.
Adverse effects Hypoglycaemic reactions—e.g., coma, nausea, vomiting, dizziness, cholestatic jaundice, agranulocytosis, aplastic and haemolytic anaemia, hypersensitivity, skin reactions including photosensitivity, rash and itching.
Precautions Hypertension, liver and kidney disease, allergies


a first generation sulfonylurea derivative, used as an oral hypoglycemic agent in the treatment of diabetes mellitus.
References in periodicals archive ?
Acetohexamide and tolazamide are not recommended even though they have mild diuretic activity, because their metabolic and excretion patterns may result in accumulation and hypoglycemia.
The flush also occurs occasionally in those taking tolbutamide, acetohexamide and tolazamide, and it occurs rarely in those taking second generation agents.
The overall frequency of side effects for first-generation agents, however, ranges between 3% and 4% for tolbutamide, acetohexamide, and tolazamide, and 9% for chlorpropamide, as compared with a side-effects frequency of 6% to to 7% for both glyburide and glipizide.
The first generation of agents, which consists of tolbutamide, tolazamide, chlorpropamide, and acetohexamide, has been in clinical use for several decades.